CJC-1295 vs Ipamorelin

What Are CJC-1295 and Ipamorelin?

CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog. Synthetic peptide analog of GHRH (first 29 amino acids) with four amino acid substitutions for enhanced stability. It is researched for increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects.

Ipamorelin (Ipamorelin) is a Growth Hormone Secretagogue (GHS) / Ghrelin mimetic. Synthetic pentapeptide derived from GHRP-1, engineered for selective GH release. It is researched for growth hormone release, improved sleep, fat loss, muscle recovery, bone density support.

While both are popular research peptides, they work through fundamentally different mechanisms and serve different primary purposes.

How Do CJC-1295 and Ipamorelin Work Differently?

CJC-1295 mechanism: CJC-1295 binds to GHRH receptors on anterior pituitary somatotrophs, stimulating growth hormone synthesis and pulsatile secretion through the cAMP-PKA signaling cascade. The 'no DAC' version has a shorter half-life, resulting in more natural GH pulses that mimic the body's endogenous rhythm rather than creating sustained supraphysiological levels.

Ipamorelin mechanism: Ipamorelin selectively stimulates GH release by mimicking ghrelin at the GHS-R receptor on pituitary somatotrophs. Unlike other GHRPs (GHRP-2, GHRP-6, Hexarelin), it does not significantly increase cortisol, prolactin, or ACTH at therapeutic doses — making it the cleanest GH secretagogue available with the fewest hormonal side effects.

These distinct mechanisms are why the two peptides are often used for different research goals — or combined to target multiple pathways.

How Do the Dosing Protocols Compare?

CJC-1295: 100-300 mcg administered 1-3 times daily, typically before bed via subcutaneous injection. Half-life: ~30 minutes (no DAC), ~8 days (with DAC). Cycle: 8-12 weeks, often paired with Ipamorelin.

Ipamorelin: 200-300 mcg administered 2-3 times daily via subcutaneous injection. Half-life: approximately 2 hours. Cycle: 8-12 weeks, often stacked with CJC-1295.

Use our peptide calculator for reconstitution math for either compound.

How Do the Benefits Compare?

CJC-1295 benefits: increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects.

Ipamorelin benefits: growth hormone release, improved sleep, fat loss, muscle recovery, bone density support.

The overlap in benefits determines whether these peptides compete for the same use case or complement each other in a stack.

How Do the Side Effects Compare?

CJC-1295: Possible water retention, tingling/numbness in hands (carpal tunnel-like), increased appetite, mild headache, and flushing at injection site. Effects are dose-dependent and typically subside with continued use.

Ipamorelin: Minimal side effects compared to other GH secretagogues. Mild headache, light-headedness, or injection site reactions possible. Does not cause the intense hunger seen with GHRP-6 or the cortisol/prolactin spikes seen with GHRP-2.

Can You Stack CJC-1295 and Ipamorelin Together?

Many researchers combine CJC-1295 and Ipamorelin in stacking protocols. The different mechanisms mean they can potentially provide complementary effects without competing for the same receptors.

The gold standard stack is CJC-1295 + Ipamorelin — GHRH + GHRP together produce GH pulses far greater than either alone, through synergistic pituitary stimulation via two distinct receptor pathways. See our stacking guide for general principles.

Which Is Better: CJC-1295 or Ipamorelin?

There is no universal answer. CJC-1295 may be preferable for researchers focused on increased growth hormone secretion, while Ipamorelin is stronger for growth hormone release.

For the most comprehensive results, many researchers combine both. Review each compound's individual guide for detailed protocols: CJC-1295 | Ipamorelin.

Frequently Asked Questions